Zhao Ping, Ji Meng-Meng, Fang Ying, Li Xiao, Yi Hong-Mei, Yan Zi-Xun, Cheng Shu, Xu Peng-Peng, Janin Anne, Wang Chao-Fu, Wang Li, Zhao Wei-Li
Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Department of Pathology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Cell Death Dis. 2021 Mar 25;12(4):321. doi: 10.1038/s41419-021-03594-y.
Long noncoding RNAs (lncRNAs) play an essential role in tumor progression. Few researches focused on the clinical and biological relevance of lncRNAs in peripheral T cell lymphoma (PTCL). In this research, a novel lncRNA (ENST00000503502) was identified overexpressed in the main subtypes of PTCL, and designated as T cell lymphoma-associated lncRNA1 (TCLlnc1). Serum TCLlnc1 was associated with extranodal involvement, high-risk International Prognostic Index, and poor prognosis of the patients. Both in vitro and in vivo, overexpression of TCLlnc1 promoted T-lymphoma cell proliferation and migration, both of which were counteracted by the knockdown of TCLlnc1 using small interfering RNAs. As the mechanism of action, TCLlnc1 directly interacted with transcription activator heterogeneous nuclear ribonucleoprotein D (HNRNPD) and Y-box binding protein-1 (YBX1) by acting as a modular scaffold. TCLlnc1/HNRNPD/YBX1 complex upregulated transcription of TGFB2 and TGFBR1 genes, activated the tumor growth factor-β signaling pathway, resulting in lymphoma progression, and might be a potential target in PTCL.
长链非编码RNA(lncRNAs)在肿瘤进展中起着至关重要的作用。很少有研究关注lncRNAs在外周T细胞淋巴瘤(PTCL)中的临床和生物学相关性。在本研究中,一种新型lncRNA(ENST00000503502)在PTCL的主要亚型中被鉴定为过表达,并被命名为T细胞淋巴瘤相关lncRNA1(TCLlnc1)。血清TCLlnc1与结外受累、高危国际预后指数以及患者的不良预后相关。在体外和体内,TCLlnc1的过表达均促进T淋巴瘤细胞的增殖和迁移,而使用小干扰RNA敲低TCLlnc1可抵消这两种作用。作为作用机制,TCLlnc1通过作为模块化支架直接与转录激活因子异质性核核糖核蛋白D(HNRNPD)和Y盒结合蛋白1(YBX1)相互作用。TCLlnc1/HNRNPD/YBX1复合物上调TGFB2和TGFBR1基因的转录,激活肿瘤生长因子-β信号通路,导致淋巴瘤进展,并且可能是PTCL的一个潜在靶点。